对心力衰竭患者的SGLT-2抑制剂的处方模式:一个双中心分析
Teja Chakrala1, Roshni O Prakash1, Justin Kim1
1Department of Medicine, University of Florida, Gainesville, FL, United States of America.
概括
葡萄糖共运输体2抑制剂 (SGLT2i) 在心力衰竭患者中显示出低处方率,尽管已证明有好处. 本研究确定了在临床实践中实施SGLT2i的障碍.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床实践 临床实践
背景情况:
- 糖共运输体2抑制剂 (SGLT2i) 减少心力衰竭 (HF) 患者的心血管死亡和住院治疗,无论糖尿病状况如何.
- 尽管有强烈的建议,但SGLT2i对心力衰竭的处方率与减少喷射率 (HFrEF) 和心力衰竭与保存喷射率 (HFpEF) 仍然很低.
研究的目的:
- 分析两个学术机构的SGLT2i处方模式.
- 确定阻碍SGLT2i在心力衰竭管理中的实施障碍.
主要方法:
- 在2021年5月至2022年5月期间入院的被诊断为心力衰竭的患者 (≥18岁) 的回顾性分析.
- 纳入标准:eGFR ≥20 mL/min/1.73m2,BNP ≥100 pg/mL. 这是一个很大的问题.
- 收集关于SGLT2i处方率和相关因素的数据.
主要成果:
- SGLT2i仅在1.8%的HFpEF和3.2%的HFrEF患者中被处方.
- 大多数HFpEF SGLT2i一般医学处方都需要心脏病学家的批准.
- 在SGLT2i使用和低血糖症或尿道感染等不良事件之间没有发现显著的关联.
结论:
- 在心力衰竭管理中SGLT2i的实施显著低,尽管已确立有效性.
- 临床实践中SGLT2i吸收的障碍需要进一步的调查和干预.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
428
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
428
01:26Heart Failure Drugs: Inotropic Agents
584
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
584
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:22Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338
01:23Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184